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The concept of molecular simplification as a drug design strategy to shorten synthetic routes, while
keeping or enhancing the biological activity of the lead drug, has been applied to (+)-muconin, an
acetogenin with remarkable cytotoxicity. A novel approach that enables the stereoselective synthesis of
such a natural compound or its enantiomer from a common precursor is described. An additional advantage
of the method is complete stereochemical control and the decrease in the number of chemical steps
required, thus providing an enhancement of the overall yield. Antiproliferative studies against the human
solid tumor cell lines showed that the aliphatic chain-THF/THP fragment of (+)-muconin has modest
cytotoxic activity. The strategy opens the way to preparing novel bioactive acetogenin analogues by
shorter synthetic routes.
Introduction
Acetogenins constitute a broad family of compounds with
interesting biological properties. From the plant family Annon-
aceae, a large number of natural acetogenins have been isolated.
These compounds have attracted the attention of many research
groups as a result of their interesting structural complexity and
the important biological activities (anticancer, pesticidal, im-
munosuppressive, and antifeedant) they exert.1 The four main
classes of structural features of annonaceous acetogenins are
mono-tetrahydrofuran, adjacent bis-tetrahydrofuran, nonadjacent
bis-tetrahydrofuran, and nonclassical acetogenins.1
(+)-Muconin (1), a nonclassical acetogenin, was isolated for
the first time by McLaughlin et al. in 1996.2 This natural product
can be split up into three parts: a long carbon chain, sequential
THF and THP rings, and a 2,4-disubstituted R,â-unsaturated
ç-lactone (Figure 1). Furthermore, this compound has eight
stereogenic centers, six of which are found in the middle part
(THF/THP rings). Focusing on the biological activity, (+)-
muconin (1) showed a potent in vitro cytotoxicity against human
pancreatic and breast tumor cells.2 In light of the interesting
biological results and its backbone novelty, some groups
dedicated their efforts to achieve its total synthesis.3
The critical issue encountered in the diverse reported total
syntheses has been to introduce in a straightforward manner
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the six stereogenic carbons present in the sequential THF/THP
moiety. In most reported syntheses,3 a common strategy is the
oxidation and subsequent stereoselective reduction of a second-
ary alcohol (Scheme 1). Although the sequence of oxidation/
reduction reactions works well and with moderate stereocontrol,
it represents an increase in the total number of synthetic steps.
Structural simplification represents a drug design strategy to
shorten synthetic routes while keeping or enhancing the biologi-
cal activity of the natural template. The concept has been applied
successfully in naturally occurring acetogenins, leading to
analogues with remarkable cytotoxicity against human solid
tumor cells.4 In acetogenins in general, the 2,4-disubstituted R,â-
unsaturated ç-lactone fragment is claimed to be essential for
the biological activity.1a However, the contribution of the other
structural fragments of these molecules to the cytotoxic activity
has not been studied in detail. We addressed our attention toward
the synthetic strategy developed by Takahashi’s group,3e since
such studies should permit analysis of the influence of the
aliphatic chain and THF/THP fragments in the cytotoxic activity
of muconin. Their strategy relies on the Sonogashira coupling
between the building blocks 2 and 3 (Scheme 2). The building
block 2 was synthesized from compound 4, which represents a
very advanced intermediate in the synthesis and in which the
six stereogenic centers are installed. Therefore, this molecular
block represents an interesting synthetic target inasmuch as its
synthesis achieved in some alternative manner represents a new
formal synthesis of the natural compound.
Within our research program directed toward the synthesis
of cyclic ethers5 and biologically active molecules,6 we report
herein on the synthesis of intermediate 4. In addition, a
preliminary structure-activity relationship (SAR) study of the
synthetic intermediates against the human ovarian cancer cell
line A2780 and the human non-small cell lung cancer (NSCLC)
cell line SW1573 is described. The application of molecular
simplification in this class of compounds is also discussed.
Recently, we have developed a reliable strategy to synthesize
polysubstituted oxanes and oxepanes with a high degree of
stereocontrol by a Nicholas reaction, based on the intramolecular
nucleophilic attack of an epoxide to a carbocation generated
by acid treatment of exo-Co2(CO)6 propargylic alcohols.7 This
synthetic tool allows us to introduce a new stereocenter at the
propargylic position with total control of the stereochemistry
(Scheme 3).
With the aforementioned methodology, we planned the
retrosynthetic analysis of 4 outlined in Scheme 4, where the
THP ring 5 (R1 ) H) would act as a scaffold. We first
disconnected the saturated chain from the terminal epoxide 6,
bearing in mind the possibility of introducing such an alkyl chain
by a nucleophilic opening of the terminal epoxide ring. The
THF ring was envisioned through a regio- and stereoselective
exo-cyclization in situ of the suitable epoxy alcohol, which in
turn could be obtained through a Katsuki-Sharpless asymmetric
(3) (a) Schaus, S. E.; Branalt, J.; Jacobsen, E. N. J. Org. Chem. 1998,
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FIGURE 1. Main structural blocs in (+)-muconin.
SCHEME 1. Common Step in Several Synthetic
Approaches to (+)-Muconin (1)
SCHEME 2. Retrosynthetic Analysis Developed by
Takahashi’s Group for the Synthesis of (+)-Muconin (1)
SCHEME 3. Epoxides as Nucleophiles in the
Intramolecular Nicholas Reaction; Strategy for the Key THP
Ring
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epoxidation (KSAE)8 of the allylic alcohol 7. Compound 7 could
be synthesized by an allyl Grignard regioselective opening of
epoxide 8 with further homologation and reduction. Compound
8 would be derived from 5 (R1 ) H) after a simple four-step
sequence: hydrogenation of the triple bond, Sharpless asym-
metric dihydroxylation (SAD) of the olefin,9 selective tosylation
of the primary alcohol, and terminal epoxide formation under
basic conditions. Three major advantages derived from this
strategy: first, the synthesis of the THF and THP stereoisomers
would be modulated by simply changing the chiral auxiliary at
the KSAE and SAD steps; second, the application of three
consecutive enantioselective reactions ensures the high enan-
tiomeric purity of the final products; third, the building block 8
could be homologated in both directions opening the possibility
to synthesize the enantiomer of compound muconin (1) starting
from the common intermediate 5.
Results and Discussions
The synthesis of 5 (R1 ) H) began with the commercially
available alcohol 5-hexen-1-ol (9), which was homologated by
a protocol recently developed in our group.10 Reduction of the
R,â-unsaturated ester 10 with DIBAL-H generated the allylic
alcohol 11. With 11 in our hands, we performed a KSAE using
as chiral auxiliary (+)-diethyl tartrate,11 followed by alcohol
protection as tert-butyl carbonate (Boc). The double bond
present in compound 12 was cleaved with OsO4/NaIO4. Thus,
the obtained aldehyde was submitted to the next step without
further purification. The coupling of this aldehyde with the
lithium salt of trimethylsilylacetylene furnished the diastereo-
meric propargylic alcohols 13. This synthetic route to 13
represents an improvement in the overall yields and in the
number of chemical steps (47% in 6 steps) on an earlier strategy
(25% in 11 steps) (Scheme 5).7
Compound 13 was then transformed into the THP 5 (R1 )
TMS) by a regio- and stereoselective intramolecular Nicholas
reaction as described earlier.6 K2CO3 treatment and diol protec-
tion with 2,2-dimethoxypropane led to the key compound 14.
The next step was the introduction of a secondary alcohol
adjacent to the THP ring, a process that proceeded with total
stereocontrol. To carry out this transformation a two-step
sequence was applied: partial hydrogenation with Lindlar
catalyst to generate the double bond in 15 and a SAD with AD-
mix R affording diol 16 as an 8:1 inseparable epimeric mixture.
Fortunately, when the primary alcohol was selectively tosylated
and reacted with NaH, pure terminal epoxide 8 was obtained.
The key epoxide 8 was then opened with allyl Grignard, in the
presence of CuI, furnishing the allylic alcohol 17. Application
of the known OsO4/NaIO4 protocol to cleave double bonds,
followed by Wittig reaction, led to the R,â-unsaturated ester
18 in good yields. Reduction with DIBAL-H allowed us to
obtain intermediate 7 (Scheme 6).
With compound 7 in hand we proceeded to the THF ring
formation. Interestingly, the KSAE of 7 using (+)-diethyl tartrate
as chiral auxiliary provided by concomitant epoxide opening
the anti-tetrahydrofuran 19 as the sole detected stereoisomer
(Scheme 7). The sequential THF/THP rings were then obtained
as a single diastereoisomer. In addition, the six stereocenters
were installed with complete stereocontrol. Compound 19 was
subjected to selective benzoylation of the primary alcohol and
further mesylation of the secondary alcohol. Basic hydrolysis
of the benzoyl ester group provided the terminal epoxide 6 by
intramolecular displacement of the secondary mesylate group
with the primary alkoxide. Finally, the regioselective opening
of the terminal epoxide with the Grignard reagent derived from
commercially available 1-bromoundecane, in the presence of
CuI, furnished the desired compound 4 achieving a formal
synthesis of (+)-muconin (1).3e
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5976. (b) Kasutki, T.; Martı´n, V. S. Organic Reactions; Paquette, L. A.,
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SCHEME 4. Retrosynthetic Analysis of Compound 4 SCHEME 5. Improved Synthesis of the Linear Precursor
13a
a Reagents and conditions: (a) SO3âPy, DMSO, TEA, Ph3PdCHCO2Et,
CH2Cl2; (b) DIBAL-H, toluene, 0 °C; (c) (i) (+)-DET, Ti(OPr-i)4, TBHP,
CH2Cl2, -20 °C (ii) toluene, DMAP, Boc2O; (d) (i) OsO4 cat., NaIO4, NMO,
THF/H2O (1:1) (ii) TMS-acetylene, n-BuLi, THF, -78 °C.
SCHEME 6. Synthesis of the Allylic Alcohol 7 Precursor of
the THF/THP Ringsa
a Reagents and conditions: (a) see ref 6; (b) (i) K2CO3, MeOH (ii) 2,2-
dimethoxypropane, CSA, CH2Cl2; (c) Lindlar catalyst, quinoleine, EtOAc;
(d) AD-mix-R, t-BuOH/H2O (1:1); (e) (i) TsCl, Py, 0 °C (ii) NaH, THF;
(f) AllylMgBr, CuI, THF; (g) (i) OsO4 cat., NaIO4, NMO, THF/H2O (1:1)
(ii) Ph3P(O)dCHCO2Et, CH2Cl2; (h) DIBAL-H, toluene, 0 °C.
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A series of the aforementioned intermediates was then
screened for growth inhibition and cytotoxicity against the
human solid tumor cell lines A2780 and SW1573 using the SRB
assay of the NCI.12 The sensitivities expressed as 50% growth
inhibition (GI50) are listed in Table 1. Interestingly, compounds
4 and 15 were the only products that reached a GI50 value within
the experimental range. Compound 4, which represents the left
half of muconin (1), showed modest GI50 values of 90 and 85
íM against A2780 and SW1573 cells, respectively. Despite the
absence of the 2,4-disubstituted R,â-unsaturated ç-lactone
fragment, which is essential for the activity of acetogenins,
intermediate 4 is able to inhibit cell growth. This effect is
masked in muconin (1) by the extraordinarily potency of the
butenolide fragment. Interestingly, compound 15 proved to be
a more potent derivative with GI50 values in the low micromolar
range, which are comparable to those of the anticancer drugs
cisplatin13 and 5-fluorouracil14 currently used in NSCLC and
ovarian cancer chemotherapy. Furthermore, compound 15 may
be considered a molecular or structural simplification of the
more complex intermediate 4, where the long aliphatic chain
and the THF ring have been replaced by a vinyl group.
Conclusions
In summary, we have accomplished a new formal and
practical synthesis of (+)-muconin (1). Total control of the six
stereocenters present in the THF/THP moiety is ensured by
means of three enantioselective reactions, and the yield in each
step is over 70%. In addition, intermediate 5 can serve as a
scaffold to obtain both enantiomers of muconin (1). Moreover,
the described methodology can be applied to other natural
products with a similar structure. In addition, the developed
methodology opens the way to synthesize other diastereoiso-
mers/enantiomers by simply changing the chiral auxiliary used
in the enantioselective reactions. Biological observations suggest
that our data could lead to the development of a new class of
structurally simplified anticancer agents. Further studies along
these lines are currently under way in our laboratories, and the
results will be reported elsewhere.
Experimental Section
Preparation of (E)-Ethyl Octa-2,7-dienoate (10). To a solution
of 5-hexen-1-ol (9) (12 mL, 99.8 mmol) in dry CH2Cl2 (400 mL)
under N2 atmosphere were added DMSO (80 mL) and triethylamine
(83 mL, 0.6 mol) at room temperature. Then, to the stirred solution
was added Ph3PdCHCO2Et (70 g, 0.2 mol), and after it was
completely dissolved, SO3âPy (48 g, 0.3 mol) was added. The
reaction was monitored by TLC until the starting material could
not be detected. Subsequently, 5% HCl solution was added until
acidic pH. Extraction with CH2Cl2 was done. The combined organic
phases were washed with water and brine, dried over MgSO4,
filtered, concentrated, and purified by column flash chromatography
to yield 13 g (80% yield) of 10. 1H NMR (300 MHz) ä 1.28 (t, J
) 7.1 Hz, 3H), 1.56 (m, 2H), 2.08 (m,2H), 2.20 (m, 2H), 4.17 (q,
J ) 7.1 Hz, 2 H), 4.99 (m, 2H), 5.79 (m, 2H), 6.95 (dt, J ) 15.5,
6.9 Hz, 1H); 13C NMR (75 MHz) ä 14.0 (q), 26.9 (t), 31.2 (t),
32.8 (t), 59.9 (t), 114.8 (t), 121.3 (d), 137.8 (d), 148.7 (d), 166.5
(s); IR (cm-1) 1367, 1443, 1654, 1721, 2933, 2980, 3078; MS (EI)
m/z (relative intensity) 54 (91), 81 (66), 95 (100), 123 (54), 140
(39), 168 (M)+ (8); HRMS (EI) calcd for C10H16O2 168.1150, found
168.1152. Anal. Calcd for C10H16O2 C 71.39, H 9.59. Found: C
71.38, H 10.02.
Preparation of (E)-Octa-2,7-dien-1-ol (11). To a solution of
10 (13 g, 77.3 mmol) in dry toluene (400 mL) under N2 atmosphere
at 0 °C was added dropwise DIBAL-H (154 mL, 0.15 mol). When
TLC indicated the complete reaction of the starting material, the
reaction was quenched by the addition of H2O. To the obtained
slurry was added MgSO4, and then the mixture was filtered through
a pad of Celite. The solvent was evaporated, and the residue was
purified by column chromatography to give 9 g (93% yield) of 11.
1H NMR (300 MHz) ä 1.48 (m, 2H), 2.04 (m, 4H), 4.07 (d, J )
4.6 Hz, 2H), 4.97 (m, 2H), 5.64 (m, 2H), 5.79 (m, 2H); 13C NMR
(75 MHz) ä 28.0 (t), 31.3 (t), 32.9 (t), 63.5 (t), 114.4 (t), 129.0 (d),
132.7 (d), 138.4 (d); IR (cm-1) 1670, 1721, 2857, 2928, 3077, 3354;
MS (EI) m/z (relative intensity) 55 (75), 67 (100), 79 (51), 93 (35),
107 (12), 125 (M - 1)+ (4); HRMS (EI) calcd for C8H14O
126.1045, found 126.1047. Anal. Calcd for C8H14O C 76.14, H
11.18. Found: C 76.16, H 11.71.
Preparation of tert-Butyl[(2S,3S)-3-(pent-4-enyl)]oxidan-2-yl]-
methyl Carbonate (12). To a solution of crushed molecular sieves
(MS 4 Å) and (+)-DET (17 mL, 99 mmol) in dry CH2Cl2 under
N2 atmosphere at -20 °C was added Ti(OPr-i)4 (25 mL, 85 mmol).
After 15 min, compound 11 was added (8.4 g, 71 mmol,) and 30
min later a 6.1 M solution of TBHP in isooctane (21 mL, 127 mmol)
was added. The reaction was stirred overnight. The reaction was
quenched by the addition of tartaric acid solution (15% in water),
and further extraction was done with CH2Cl2. The extracts were
dried over MgSO4, and the solvent was evaporated under reduced
pressure. The residue obtained was dissolved in ether and washed
with NaOH solution (15% in water). The organic phase was dried
with MgSO4 and filtered. Following solvent evaporation the residue
was employed in the next step without further purification.
(12) Skehan, P.; Storeng, P.; Scudeiro, D.; Monks, A.; McMahon, J.;
Vistica, D.; Warren, J. T.; Bokesch, H.; Kenney, S.; Boyd, M. R. J. Natl.
Cancer Inst. 1990, 82, 1107-1112.
(13) (a) Van Moorsel, C. J.; Smid, K.; Voorn, D. A.; Bergman, A. M.;
Pinedo, H. M.; Peters, G. J. Int. J. Oncol. 2003, 22, 201-207. (b) Fokkema,
E.; Groen, H. J.; Helder, M. N.; de Vries, E. G.; Meijer, C. Biochem.
Pharmacol. 2002, 63, 1989-1996.
(14) Bergman, A. M.; Giaccone, G.; van Moorsel, C. J.; Mauritz, R.;
Noordhuis, P.; Pinedo, H. M.; Peters, G. J. Eur. J. Cancer 2000, 36, 1974-
1983.
SCHEME 7. Completion of the Formal Synthesis of
(+)-Muconin (1)a
a Reagents and conditions: (a) (+)-DET, Ti(OPr-i)4, TBHP, CH2Cl2,
-20 °C; (b) (i) TEA, benzoyl chloride, then MsCl, CH2Cl2 (ii) MeOH,
NaH, CH2Cl2, 0 °C; (c) bromoundecane, Mg, CuI, THF, -78 °C.
TABLE 1. In Vitro Cytotoxic Activity (GI50) against Human Solid
Tumor Cellsa
cell line
compound A2780 SW1573
4 90 ( 18 85 ( 20
7 >100 >100
8 >100 >100
15 18 ( 11 24 ( 5
16 >100 >100
17 >100 >100
18 >100 >100
19 >100 >100
a Values are given in íM and are means of at least three experiments;
standard deviation is given.
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To a solution of the aforementioned crude epoxy alcohol in dry
toluene (280 mL) under N2 atmosphere and at room temperature
was added Boc anhydride (19 g, 85 mmol) followed by DMAP
(867 mg, 7.1 mmol). The reaction was monitored by TLC and was
complete after 2 h. The reaction mixture was treated with CHCl3
and HCl solution (5% in water) and extracted with more CHCl3.
The organic phase was dried and concentrated. Chromatography
on silica gel afforded 14.5 g (85% yield) of 12. [R]25D ) -19.9 (c
1.1, CHCl3); 1H NMR (300 MHz) ä 1.48 (s, 9H), 1.47-1.57 (m,
4H), 2.08 (m, 2H), 2.85 (m, 1H), 2.97 (m, 1H), 4.00 (dd, J ) 5.8,
12.0 Hz, 1H), 4.22 (dd, J ) 3.8, 12.0 Hz, 1H), 4.97 (m, 2H), 5.76
(m, 1H);13C NMR (75 MHz) ä 24.8 (t), 27.5 (q), 30.6 (t), 33.0 (t),
54.8 (d), 56.3 (d), 66.8 (t), 82.3 (s), 114.7 (t), 137.9 (d), 153.0 (s);
IR (cm-1) 1370, 1641, 1744, 2862, 2980, 3077; MS (FAB) m/z
(relative intensity) 57 (100), 107 (41), 137 (14), 154 (9), 187 (33),
243 (M + 1)+ (8); HRMS (FAB) calcd for C13H23O4 (M + 1)+
243.1596, found 243.1595. Anal. Calcd for C13H22O4 C 64.44, H
9.15. Found: C 64.44, H 9.53.
Preparation of tert-Butyl{(2R,3R)-3-[4-hydroxy-6-(trimeth-
ylsilyl)hex-5-ynyl]oxiran-2-yl}methyl Carbonate (13). Compound
12 (14 g, 57.8 mmol) was dissolved in THF/H2O 1:1 (350 mL) at
room temperature. To this solution were added NMO (17 g, 0.14
mol) and a catalytic amount of OsO4. The reaction mixture was
stirred overnight, quenched with a saturated solution of Na2S2O3,
and extracted with EtOAc. The organic phase was dried, and the
solvent was evaporated under reduced pressure. The crude aldehyde
obtained was used in the next step without purification.
To a solution of ethynyltrimethylsilane (9 mL, 63.5 mmol) in
dry THF under N2 atmosphere at -78 °C was added a solution of
n-BuLi (2.1 M, 30 mL). After 30 min at the same temperature the
crude aldehyde was added. The reaction was quenched by addition
of a saturated solution of NH4Cl, and the extraction was done with
Et2O. The organic phase was dried over MgSO4, and the solvent
was evaporated under reduced pressure. Purification by chromato-
graphic column afforded 14.8 g (75% yield) of 13. 1H NMR (300
MHz) ä 0.17 (s, 9H), 1.49 (s, 9H), 1.57-1.86 (m, 6H), 2.88 (m,
1H), 2.99 (m, 1H), 4.01 (dd, J ) 5.8, 12.0 Hz, 1H), 4.24 (dd, J )
3.7, 12.0 Hz, 1H), 4.36 (m, 1H); 13C NMR (75 MHz) ä -0.4 (q),
21.4 (t), 27.5 (q), 30.8 (t), 36.9 (t), 57.7 (d), 56.2 (d), 62.4 (d),
66.7 (t), 82.3 (s), 89.5 (s), 106.2 (s), 153.0 (s); IR (cm-1) 1281,
1370, 1745, 2170, 2957, 3459; MS (FAB) m/z (relative intensity)
57 (95), 73 (100), 137 (25), 154 (23), 181 (9), 269 (30); HRMS
(FAB) calcd for C17H30O5SiNa (M + Na)+ 365.1760, found
365.1768. Anal. Calcd for C17H30O5Si C 59.61, H 8.83. Found: C
59.61, H 8.89.
Preparation of (R)-1-{(2S,6R)-6-[2-(Trimethylsilyl)ethynyl]-
tetrahydro-2H-pyra-2-yl}ethane-1,2-diol (5). To a solution of 13
(8.52 g, 24.9 mmol) in dry CH2Cl2 under N2 atmosphere and at
room temperature was added Co2(CO)8 (9.36 g, 27.3 mmol). The
reaction was monitored by TLC until the starting material was
completely consumed. To the solution of the hexacarbonyldicobalt
complex of 13 was added BF3âOEt2 (3.15 mL, 24.9 mmol) at room
temperature. The reaction mixture was stirred for 3 h. The mixture
was poured with vigorous stirring into a saturated solution of
NaHCO3 at 0 °C and extracted with CH2Cl2. The combined organic
phases were washed with brine, dried (MgSO4), and concentrated.
The crude mixture was dissolved in acetone (2.1 mL) at 0 °C. Ceric
ammonium nitrate (41.0 g, 74.7 mmol) was added in portions with
stirring until evolution of CO ceased and the CAN color persisted
(30 min). The solvent was removed under vacuum, and the pink
solid residue was then partitioned between Et2O and H2O. The
aqueous phase was extracted additionally twice with Et2O. The
combined organic extracts were dried, filtered, concentrated, and
subjected to silica gel flash chromatography yielding compound 5
in 70% yield (4.2 g). [R]25D ) -26.6 (c 0.7, CHCl3); 1H NMR
(300 MHz) ä 0.15 (s, 9H), 1.48-1.65 (m, 5H), 1.80-1.92 (m, 3H),
3.45 (m, 1H), 3.65 (m, 1H), 3.75 (m, 2H), 4.10 (dd, J ) 2.3, 11.1
Hz, 1H); 13C NMR (75 MHz) ä -0.4 (q), 22.6 (t), 26.0 (t), 32.3
(t), 63.1 (t), 68.7 (d), 73.3 (d), 79.8 (d), 89.0 (s), 104.2 (s); IR
(cm-1) 1063, 1250, 1715, 2179, 2954, 3384; MS (EI) m/z (relative
intensity) 73 (100), 97 (29), 109 (15), 125 (84), 181 (34), 242 (M)+
(3); HRMS (EI) calcd for C12H22O3Si (M)+ 242.1338, found
242.1331. Anal. Calcd for C12H22O3Si C 59.46, H 9.15. Found: C
59.44, H 9.01.
Preparation of (2S,6R)-2-[(R)-2,2-Dimethyl-1,3-dioxolan-4-yl]-
6-ethynyl-tetrahydro-2H-pyran (14). To a solution of 5 (3.52 g,
14.5 mmol) in methanol (50 mL) at room temperature was added
K2CO3 (1.0 g, 7.2 mmol). After 6 h the reaction was completed.
To the reaction mixture was added CH2Cl2, and the mixture was
filtered through a pad of Celite. The solvent was evaporated under
reduced pressure, and the resulting residue was employed in the
next step without purification.
This crude was dissolved in dry CH2Cl2 (50 mL) under N2
atmosphere and at room temperature. To the solution were added
2,2-dimethoxypropane (2.7 mL, 21.7 mmol) and camphor-10-
sulfonic acid (1.68 g, 7.2 mmol). The reaction was monitored by
TLC, and after 3 h starting material was not observed. A saturated
solution of NaHCO3 was added to the reaction mixture, and the
mixture was extracted with CH2Cl2. The organic phase was dried
and the solvent evaporated. Column chromatography afforded 2.35
g (78% yield) of compound 14. [R]25D ) -44.1 (c 1.1, CHCl3); 1H
NMR (300 MHz) ä 1.33 (s, 3H), 1.39 (s, 3H), 1.26-1.68 (m, 3H),
1.80-1.87 (m, 3H), 2.45 (d, J ) 2.1 Hz, 1H), 3.24 (m, 1H), 3.91-
3.97 (m, 2H), 4.04-4.13 (m, 2H); 13C NMR (75 MHz) ä 22.4 (t),
25.0 (q), 26.5 (q), 27.2 (t), 32.3 (t), 67.1 (t), 67.7 (d), 72.3 (d),
77.7 (d), 79.0 (d), 82.8 (s), 109.0 (s); IR (cm-1) 1371, 1719, 2120,
2860, 2942, 3284; MS (FAB) m/z (relative intensity) 55 (100), 69
(65), 81 (73), 101 (75), 154 (52), 210 (M)+ (4); HRMS (FAB)
calcd for C12H18O3 (M)+ 210.1256, found 210.1258. Anal. Calcd
for C12H18O3 C 68.54, H 8.63. Found: C 68.64, H 8.85.
Preparation of (2S,6R)-2-[(R)-2,2-Dimethyl-1,3-dioxolan-4-yl]-
6-vinyl-tetrahydro-2H-pyran (15). A mixture of compound 14
(1.79 g, 8.5 mmol), Lindlar catalyst (89 mg, 5% w), and quinoline
(4 íL, 0.2% w) in dry EtOAc (50 mL) was stirred at room
temperature under H2 atmosphere (1 atm) for 1 h. After this time,
TLC showed complete conversion. The solution was filtered through
a pad of Celite, and the filter cake was washed with EtOAc. After
purification by chromatographic column, 1.79 g (99% yield) of
compound 15 was obtained. [R]25D ) -38.1 (c 1.0, CHCl3); 1H
NMR (300 MHz) ä 1.35 (s, 3H), 1.40 (s, 3H), 1.23-1.67 (m, 4H),
1.79-1.92 (m, 2H), 3.32 (m, 1H), 3.84 (m, 1H), 3.95 (m, 2H),
4.05 (m, 1H), 5.06 (dt, J ) 10.6, 1.4 Hz, 1H), 5.19 (dt, J ) 17.3,
1.6 Hz, 1H), 5.83 (ddd, J ) 17.3, 10.6, 5.3 Hz, 1H); 13C NMR (75
MHz) ä 22.6 (t), 25.0 (q), 26.4 (q), 27.5 (t), 31.0 (t), 66.8 (t), 77.9
(d), 78.0 (d), 78.2 (d), 108.8 (s), 114.1 (t), 138.8 (d); IR (cm-1)
1075, 1212, 1370, 2859, 2936, 2986; MS (EI) m/z (relative intensity)
67 (100), 93 (95), 101 (52), 111 (79), 197 (54), 212 (M)+ (1);
HRMS (EI) calcd for C12H20O3 (M - 1)+ 211.1334, found
211.1342. Anal. Calcd for C12H20O3 C 67.89, H 9.50. Found: C
67.87, H 9.67.
Preparation of (R)-1-{(2R,6S)-6-[(R)-2,2-Dimethyl-1,3-diox-
olan-4-yl]-tetrahydro-2H-pyran-2-yl}ethane-1,2-diol (16). Com-
pound 15 was added to a mixture of t-BuOH (43 mL), H2O (43
mL), and AD-mix-R (11.83 g, 1.4 g/mmol of 15) at 0 °C. The
solution was stirred for 12 h at 0 °C. After addition of a saturated
Na2SO3 solution (50 mL) the mixture was extracted with EtOAc.
The extracts were dried, and the solvent was removed. Flash
chromatography yielded 16 (1.70 g, 83% yield). [R]25D ) -6.6 (c
1.1, CHCl3); 1H NMR (300 MHz) ä 1.32 (s, 3H), 1.40 (s, 3H),
1.17-1.53 (m, 3H), 1.72 (m, 2H), 1.93 (m, 1H), 3.35 (m, 1H),
3.43 (m, 1H), 3.56 (m, 1H), 3.68 (m, 2H), 3.85-4.02 (m, 3H); 13C
NMR (75 MHz) ä 22.2 (t), 25.0 (q), 26.3 (q), 27.0 (t), 27.6 (t),
63.2 (t), 66.2 (t), 73.5 (d), 77.9 (d), 78.2 (d), 79.3 (d), 109.1 (s); IR
(cm-1) 1212, 1371, 2861, 2936, 2985, 3417; MS (FAB) m/z (relative
intensity) 81 (55), 132 (78), 189 (54), 231 (60), 247 (M + 1)+
(100), 269 (M + Na)+ (64); HRMS (FAB) calcd for C12H22O5 (M)+
246.1467, found 246.1464. Anal. Calcd for C12H22O5 C 58.52, H
9.00. Found: C 58.51, H 9.10.
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Preparation of (2S,6R)-2-[(R)-2,2-Dimethyl-1,3-dioxolan-4-yl]-
6-[(R)-oxiran-2-yl]-tetrahydro-2H-pyran (8). To a stirred solution
of 16 (1.5 g, 6.1 mmol) in dry pyridine (30.5 mL, 0.2 M) was
added TsCl (1.39 g, 7.3 mmol) at 0 °C. The reaction mixture was
stirred for 6 h, after which time TLC showed the end, and then
diluted with H2O, and the aqueous layer was extracted with Et2O.
The ethereal extracts were washed with H2O, saturated CuSO4
solution, and saturated NaCl solution (60 mL), dried, and concen-
trated. The residue monotosylated alcohol was used in the next step
without purification.
The crude was dissolved in dry THF (61 mL) under N2
atmosphere at room temperature, and NaH (60%, 175 mg, 12.2
mmol) was added. After 4 h, TLC showed that starting material
was completely consumed. The reaction was quenched by addition
of a saturated solution of NaCl, and the mixture was extracted with
Et2O. The organic phase was dried, and the solvent was evaporated
under reduced pressure. Purification by chromatographic column
gave 1.01 g (73% yield) of epoxide 8. [R]25D ) -6.0 (c 0.7, CHCl3);
1H NMR (300 MHz) ä 1.35 (s, 3H), 1.41 (s, 3H), 1.24-1.91 (m,
6H), 2.67 (dd, J ) 2.6, 5.2 Hz, 1H), 2.75 (dd, J ) 4.1, 5.2 Hz,
1H), 2.94 (m, 1H), 3.25 (m, 2H), 3.88-4.05 (m, 3H); 13C NMR
(75 MHz) ä 22.1 (t), 25.1 (q), 26.4 (q), 27.5 (t), 44.9 (t), 53.2 (t),
53.5 (d), 66.7 (t), 77.2 (d), 77.9 (d), 78.4 (d), 109.3 (s); IR (cm-1)
1092, 1370, 1456, 2861, 2937, 2986; MS (FAB) m/z (relative
intensity) 55 (100), 69 (90), 83 (61), 95 (50), 213 (16), 229 (M +
1)+ (16); HRMS (FAB) calcd for C12H21O4 (M + 1)+ 229.1440,
found 229.1441. Anal. Calcd for C12H20O4 C 63.14, H 8.83.
Found: C 63.14, H 9.19.
Preparation of (1R)-1-{(2R,6S)-6-[(R)-2,2-Dimethyl-1,3-diox-
olan-4-yl]-tetrahydro-2H-pyran-2-yl}penten-4-en-1-ol (17). To
a mixture of CuI (75 mg, 0.4 mmol) in dry THF (40 mL) under
argon atmosphere was added allylmagnesium bromide (11.8 mL,
1 M in THF, 11.8 mmol) at -78 °C. The mixture was stirred for
10 min, and epoxide 6 (900 mg, 3.9 mmol) was added dropwise.
TLC showed almost instant conversion. The reaction was quenched
with a saturated aqueous solution of NH4Cl. The layers were
partitioned, and the aqueous phase was extracted with Et2O. The
combined organic layers were dried, filtered, and concentrated to
yield a crude oil, which was purified by chromatographic column
to obtain 1.00 g (94% yield) of compound 17. [R]25D ) -8.3 (c
0.6, CHCl3); 1H NMR (300 MHz) ä 1.35 (s, 3H), 1.40 (s, 3H),
1.18-1.65 (m, 6H), 1.80 (m, 1H), 1.91-2.13 (m, 3H), 2.25 (m,
1H), 3.31 (m, 2H), 3.62 (m, 1H), 3.91 (m, 2H), 4.02 (m, 1 H),
5.01 (m, 2H), 5.83 (m, 1H); 13C NMR (75 MHz) ä 22.3 (t), 24.6
(t), 25.1 (q), 26.5 (q), 28.0 (t), 29.8 (t), 31.0 (t), 66.8 (t), 72.8 (d),
78.1(d), 78.6 (d), 80.1 (d), 109.0 (s), 114.6 (t), 138.2 (d); IR (cm-1)
1370, 1640, 2858, 2937, 3076, 3472; MS (EI) m/z (relative intensity)
66 (84), 81 (96), 133 (44), 169 (69), 255 (100), 270 (M + 1)+ (1);
HRMS (EI) calcd for C15H26O4 (M)+ 270.1831, found 270.1835.
Anal. Calcd for C15H26O4 C 66.64, H 9.69. Found: C 66.56, H
9.86.
Preparation of Ethyl (2E,6R)-6-{(2R,6S)-6-[(4R)-2,2-Dimeth-
yl-1,3-dioxolan-4-yl]-tetrahydro-2H-pyran-2-yl}-6-hydroy-2-
hexenoate (18). Compound 17 (900 mg, 3.33 mmol) was dissolved
in a 1:1 mixture of THF/H2O (35 mL) at room temperature. To
this solution were added NMO (1.01 g, 8.32 mmol) and a catalytic
amount of OsO4. The reaction mixture was stirred overnight,
quenched with a saturated solution of Na2S2O3, and extracted with
EtOAc. The organic phase was dried, and the solvent was
evaporated under reduced pressure. The crude aldehyde obtained
was used in the next step without purification.
To a solution of the crude aldehyde in CH2Cl2 (35 mL) under
N2 atmosphere at room temperature was added Ph3PdCHCO2Et
(2.32 g, 6.66 mmol). After 4 h the reaction was completed. The
reaction was quenched with H2O, and extraction was done with
CH2Cl2. The organic phase was dried, and the solvent was
evaporated under reduced pressure. Chromatographic purification
gave 1.02 g (90% yield) of the ester 18. [R]25D ) -2.8 (c 1.1,
CHCl3); 1H NMR (300 MHz) ä 1.26 (t, J ) 7.1 Hz, 3H), 1.33 (s,
3H), 1.38 (s, 3H), 1.16-1.59 (m, 5H), 1.79 (m, 1H), 1.91 (m, 1H),
2.09-2.40 (m, 3H), 3.29 (m, 2H), 3.58 (m, 1H), 3.87 (m, 2H),
4.02 (m, 1H), 4.16 (q, J ) 7.1 Hz, 2H), 5.82 (d, J ) 15.6 Hz, 1H),
6.96 (dt, J ) 6.9, 15.4 Hz, 1H); 13C NMR (75 MHz) ä 14.0 (q),
22.2 (t), 24.8 (t), 25.1 (q), 26.4 (q), 27.9 (t), 28.3 (t), 30.2 (t), 59.9
(t), 66.7 (t), 72.5 (d), 78.0 (d), 78.6 (d), 80.0 (d), 109.0 (s), 121.4
(d), 148.5 (d), 166.4 (s); IR (cm-1) 1370, 1652, 1719, 2860, 2938,
3487; MS (FAB) m/z (relative intensity) 55 (83), 67 (65), 83 (58),
101 (50), 327 (65), 343 (M + 1)+ (100); HRMS (FAB) calcd for
C18H31O6 (M + 1)+ 343.2121, found 343.2120. Anal. Calcd for
C18H30O6 C 63.14, H 8.83. Found: C 63.14, H 9.67.
Preparation of (2E,6R)-6-{(2R,6S)-6-[(R)-2,2-Dimethyl-1,3-
dioxolan-4-yl]-tetrahydro-2H-pyran-2-yl}hex-2-ene-1,6-diol (7).
To a solution of 18 (900 mg, 2.6 mmol) in toluene (26 mL) under
N2 atmosphere at 0 °C was added DIBAL-H (7.9 mL, 7.9 mmol).
When TLC indicated the complete conversion of the starting
material, the reaction was quenched by addition 0.25 mL of H2O.
To the slurrish solution obtained was added MgSO4, and it was
filtered through a pad of Celite. The solvent was evaporated, and
the residue was purified by chromatographic column to give 630
mg of 7 (80% yield). [R]25D ) -6.4 (c 1.9, CHCl3); 1H NMR (300
MHz) ä 1.34 (s, 3H), 1.39 (s, 3H), 1.22-1.59 (m, 6H), 1.76-2.24
(m, 6H), 3.29 (m, 2H), 3.60 (m, 1H), 3.86-4.08 (m, 5H), 5.67 (m,
2H); 13C NMR (75 MHz) ä 22.3 (t), 24.6 (t), 25.1 (q), 26.4 (q),
27.9 (t), 28.3 (t), 31.2 (t), 63.3 (t), 66.6 (t), 72.7 (d), 78.0 (d), 78.5
(d), 80.1 (d), 109.0 (s), 129.2 (d), 132.3 (d); IR (cm-1) 1074, 1371,
1669, 2858, 2936, 3415; MS (FAB) m/z (relative intensity) 55 (100),
73 (98), 147 (43), 221 (16), 281 (13), 300 (M)+ (1); HRMS (FAB)
calcd for C16H28O5 (M)+ 300.1937, found 300.1926. Anal. Calcd
for C16H28O5 C 63.97, H 9.40. Found: C 63.84, H 9.08.
Preparation of (S)-1-((2R,5R)-5-{(2R,6S)-6-[(R)-2,2-Dimethyl-
1,3,dioxolan-4-yl]-tetrahydro-2H-pyran-2-yl}-tetrahydrofuran-
2-yl)ethane-1,2-diol (19). Crushed, activated 4 Å molecular sieves
were added to stirred CH2Cl2 (2.5 mL) under argon. The flask was
cooled to -20 °C, and Ti(OPr-i)4 (0.16 mL, 0.5 mmol), (+)-DET
(0.11 mL, 0.6 mmol), and the allylic alcohol 7 (134 mg, 0.45 mmol)
in CH2Cl2 (2.5 mL) were added sequentially with stirring. The
mixture was stirred at the same temperature for 20 min, and TBHP
(0.15 mL, 6.1 M in isooctane, 0.80 mmol) was added slowly. After
the addition, the reaction was maintained with stirring for 2 h.
Tartaric acid aqueous solution (15% w/v) was added at room
temperature, and the stirring was continued until clear phases were
reached (ca. 1 h). The phases were separated, and the aqueous phase
was extracted with CH2Cl2. The combined organic phases were
washed with brine, concentrated, diluted with Et2O, and treated
with precooled (0 °C) 15% (w/v) NaOH aqueous solution. The two-
phase mixture was stirred vigorously for 15 min at 0 °C. The organic
phase was separated, and the aqueous phase was extracted with
CH2Cl2. The combined organic phases were washed with brine,
dried, filtered, concentrated, and purified by silica gel column
chromatography to yield 19 (106 mg, 75% yield). [R]25D ) -3.0
(c 0.7, CHCl3); 1H NMR (300 MHz) ä 1.21 (m, 2H), 1.34 (s, 3H),
1.39 (s, 3H), 1.46 (m, 1H), 1.68-1.99 (m, 7H), 2.32 (m, 1H), 2.46
(m, 1H), 3.25 (m, 2H), 3.67 (m, 3H), 3.89 (m, 4H), 4.00 (m, 1H);
13C NMR (75 MHz) ä 22.4 (t), 25.1 (q), 26.5 (q), 26.9 (q), 27.5
(t), 27.7 (t), 28.0 (t), 63.7 (t), 66.7 (t), 72.7 (d), 78.1 (d), 78.4 (d),
79.9 (d), 80.4 (d), 81.6 (d), 109.0 (s); IR (cm-1) 1211, 1371, 1648,
2935, 2983, 3421; MS (FAB) m/z (relative intensity) 55 (89), 69
(100), 81 (59), 109 (27), 154 (14), 339 (M + Na)+ (10); HRMS
(FAB) calcd for C16H28O6Na (M + Na)+ 339.1784, found 339.1798.
Anal. Calcd for C16H28O6 C 60.74, H 8.92. Found: C 60.82, H
8.67.
Preparation of (2S,6R)-2-[(R)-2,2-Dimethyl-1,3-dioxolan-4-yl]-
6-{(2R,5R)-5-[(R)-oxiran-2-yl]-tetrahydrofuran-2-yl}-tetrahydro-
2H-pyran (6). To a solution of 19 (95 mg, 0.30 mmol) in dry
CH2Cl2 (6 mL) under argon atmosphere were sequentially added
Et3N (0.06 mL, 0.45 mmol) and benzoyl chloride (0.047 mL, 0.36
mmol) at 0 °C. The reaction was stirred for 2 h, after which time
TLC showed that the starting material had disappeared. Then
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saturated aqueous solution of NaCl was added, and the resulting
mixture was extracted with CH2Cl2. The combined organic phases
were dried, filtered, and evaporated under reduced pressure to yield
a residue, which was used in the next step without any further
purification. To a stirred mixture of the crude monobenzoate in
dry CH2Cl2 (6 mL) under argon atmosphere were added Et3N (0.06
mL, 0.45 mmol) and methanesulfonyl chloride (0.05 mL, 0.72
mmol) at 0 °C. The reaction mixture was stirred for 1 h, after which
time TLC showed no remaining alcohol. Then, a saturated aqueous
solution of NaCl was added, and the resulting mixture was extracted
with CH2Cl2. The combined organic phases were dried, filtered,
and evaporated under reduced pressure.
To a cooled suspension of NaH (36 mg, 60% in mineral oil, 0.9
mmol) in dry CH2Cl2 (6 mL) under argon atmosphere was added
dropwise dry MeOH (0.4 mL, 0.9 mmol) at 0 °C. The mixture was
stirred for 15 min, and the residue obtained above was added slowly.
After the addition, the mixture was allowed to warm to room
temperature until the TLC showed no remaining benzoate. Then a
saturated aqueous solution of NaCl was added, the aqueous phase
was extracted with CH2Cl2, and the combined organic phases were
dried, filtered, and concentrated. Purification was effected by flash
column chromatography to yield 6 (73 mg, 82% yield). [R]25D )
-9.0 (c 0.5, CHCl3); 1H NMR (300 MHz) ä 1.21 (m, 3H), 1.34 (s,
3H), 1.39 (s, 3H), 1.64-1.86 (m, 6H), 2.02 (m, 2H), 2.66 (dd, J )
2.7, 5.1 Hz, 1H), 2.74 (dd, J ) 4.2, 5.1 Hz, 1H), 2.95 (m, 1H),
3.24 (m, 1H), 3.81-3.91 (m, 4H), 3.99 (m, 1H); 13C NMR (75
MHz) ä 22.4 (t), 25.2 (q), 26.5 (q), 27.5 (t), 28.0 (t), 28.1 (t), 28.4
(t), 43.8 (t), 53.9 (d), 66.8 (t), 78.1 (d), 78.4 (d), 78.7 (d), 79.9 (d),
82.1 (d), 109.0 (s); IR (cm-1) 1210, 1370, 1456, 2860, 2934, 2984;
MS (FAB) m/z (relative intensity) 55 (100), 69 (73), 81 (60), 109
(29), 132 (16), 297 (M - 1)+ (6); HRMS (FAB) calcd for C16H25O5
(M - 1)+ 297.1702, found 297.1709. Anal. Calcd for C16H26O5 C
64.41, H 8.78. Found: C 64.39, H 9.40.
Preparation of (1R)-1-((2R,5R)-5-{(2R,6S)-6-[(4R)-2,2-Dimethyl-
1,3-dioxolan-4-yl]tetrahydro-2H-pyran-2-yl}tetrahydro-2-fura-
nyl)-1-tridecanol (4). To a mixture of CuI (4 mg, 0.02 mmol) in
dry THF (2 mL) under argon atmosphere at -78 °C was added
undecanemagnesium bromide, previously formed from bromoun-
decane (195 mg, 0.83 mmol) and magnesium turnings (20 mg, 0.8
mmol) at room temperature. The mixture was stirred for 10 min,
and epoxide 6 (62 mg, 0.2 mmol) dissolved in dry THF (2 mL)
was added slowly. TLC showed almost instant conversion. The
reaction was quenched with a saturated aqueous solution of NH4Cl.
The layers were partitioned, and the aqueous phase was extracted
with Et2O. The combined organic layers were dried, filtered, and
concentrated to yield a crude oil, which was purified by chromato-
graphic column to obtain 66 mg (70% yield) of compound 4. [R]25D
) +16.5 (c 0.4, CHCl3) {lit. [R]25D ) +17.8 (c 0.23, CHCl3)}3e;
1H NMR (300 MHz) ä 0.87 (t, J ) 4.7 Hz, 3H), 1.34 (s, 3H), 1.39
(s, 3H), 1.18-1.91 (m, 34 H), 3.28 (m, 2H), 3.79 (m, 2H), 3.93
(m, 2H), 4.05 (m, 1H); 13C NMR ä (75 MHz) ä 13.9 (q), 22.3 (t),
22.4 (t), 25.1 (q), 25.4 (t), 26.5 (q), 27.9 (t), 28.0 (t), 28.3 (t), 29.1
(t), 29.4 (t), 29.5 (t), 31.7 (t), 33.3 (t), 66.8 (t), 73.8 (d), 78.1 (d),
78.5 (d), 80.0 (d), 81.3 (d), 82.6 (d), 109.0 (s); IR (cm-1) 1371,
1460, 2856, 2926, 2983, 3495; MS (EI) m/z (relative intensity) 127
(22), 197 (49), 255 (100), 353 (13), 440 (4), 454 (M)+ (0.4); HRMS
(EI) calcd for C27H50O5 (M)+ 454.3658, found 454.3669.
Biological Tests. Cells, Culture, and Plating. The human solid
tumor cell lines A2780 (ovarian and SW1573 (nonsmall cell lung
cancer) were used in this study. Cells were maintained in 25 cm2
culture flasks in RPMI 1640 supplemented with 5% heat-inactivated
fetal calf serum and 2 mM l-glutamine in a 37 °C, 5% CO2, 95%
humidified air incubator. Exponentially growing cells were trypsinized
and resuspended in antibiotic containing medium (100 units
penicillin G and 0.1 mg of streptomycin/mL). Single cell suspen-
sions displaying >97% viability by trypan blue dye exclusion were
subsequently counted. After counting, dilutions were made to give
the appropriate cell densities for inoculation onto 96-well microtiter
plates. Cells were inoculated in a volume of 100 mL per well at
densities of 7,000 (A2780) and 6,000 (SW1573) cells per well,
based on their doubling times.
Chemosensitivity Testing. Chemosensititvity tests were per-
formed using the SRB assay of the NCI.12 Pure compounds were
initially dissolved in DMSO at 400 times the desired final maximum
test concentration. Control cells were exposed to an equivalent
concentration of DMSO (negative control). Each agent was tested
in triplicates at different dilutions in the range 1-100 íM. The
drug treatment was started on day 1 after plating. Drug incubation
times were 48 h, after which time cells were precipitated with 25
íL ice-cold 50% (w/v) trichloroacetic acid and fixed for 60 min at
4 °C. Then the SRB assay was performed. The optical density (OD)
of each well was measured at 490 nm, using BioTek’s ELx800NB
absorbance microplate reader. Values were corrected for background
OD from wells only containing medium. The effect is defined as
percentage of growth (PG) and was calculated with respect to
untreated control cells (C) at each of the drug concentration levels
based on the difference in OD at the start (T0) and end of drug
exposure (T), according to NCI formulas. Briefly, if T is greater
than or equal to T0 the calculation is 100  [(T - T0)/(C - T0)].
If T is less than T0 denoting cell killing the calculation is 100 
[(T - T0)/(T0)]. With these calculations a PG value of 0 corresponds
to the amount of cells present at the start of drug exposure, while
negative PG values denote net cell kill. Thus, 50% growth inhibition
(GI50) represents the concentration at which PG is +50.
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